Immunogenicity of plant-produced African horse sickness virus-like particles : implications for a novel vaccine

dc.contributor.authorDennis, Susan J.
dc.contributor.authorMeyers, Ann E.
dc.contributor.authorGuthrie, Alan John
dc.contributor.authorHitzeroth, Inga I.
dc.contributor.authorRybicki, Edward P.
dc.date.accessioned2017-08-25T05:57:30Z
dc.date.available2017-08-25T05:57:30Z
dc.date.issued2018-02
dc.descriptionFigure S1 Optimization of plant-based expression of recombinant AHSV-5 structural proteins.en_ZA
dc.descriptionFigure S2 Increased formation of AHSV-5 VLPs incorporating a mutated version of VP7.en_ZA
dc.descriptionFigure S3 Purification of AHSV-5 VLPs.en_ZA
dc.descriptionFigure S4 Mass spectrometry analysis of the 4 protein bands recovered from SDS-PAGE separation of density gradient fractions from leaves co-infiltrated with Agrobacterium AGL1 pEAQ recombinants for co-expression of AHSV capsid proteins VP2, VP3, VP5 and VP7mu.en_ZA
dc.descriptionFigure S5 Quantification of AHSV-5 VLPs by gel densitometry.en_ZA
dc.descriptionTable S1 Virus neutralizing antibody titres of serum samples from vaccinated and control guinea pigs V1 and C1.en_ZA
dc.description.abstractAfrican horse sickness (AHS) is a debilitating and often fatal viral disease affecting horses in much of Africa, caused by the dsRNA orbivirus African horse sickness virus (AHSV). Vaccination remains the single most effective weapon in combatting AHS, as there is no treatment for the disease apart from good animal husbandry. However, the only commercially available vaccine is a liveattenuated version of the virus (LAV). The threat of outbreaks of the disease outside its endemic region and the fact that the LAV is not licensed for use elsewhere in the world, have spurred attempts to develop an alternative safer, yet cost-effective recombinant vaccine. Here, we report the plant-based production of a virus-like particle (VLP) AHSV serotype five candidate vaccine by Agrobacterium tumefaciens-mediated transient expression of all four capsid proteins in Nicotiana benthamiana using the cowpea mosaic virus-based HyperTrans (CPMV-HT) and associated pEAQ plant expression vector system. The production process is fast and simple, scalable, economically viable, and most importantly, guinea pig antiserum raised against the vaccine was shown to neutralize live virus in cell-based assays. To our knowledge, this is the first report of AHSV VLPs produced in plants, which has important implications for the containment of, and fight against the spread of, this deadly disease.en_ZA
dc.description.departmentEquine Research Centreen_ZA
dc.description.librarianam2017en_ZA
dc.description.sponsorshipThis research was supported by the Technology and Innovation Agency. SD was supported by funding from the Technology and Innovation Agency and the Poliomyelitis Research Foundation and received conference travel funding from the National Research Foundation, the UCT Postgraduate Funding Office and WhiteSci.en_ZA
dc.identifier.citationDennis, S. J., Meyers, A. E., Guthrie, A. J., Hitzeroth, I. I. and Rybicki, E. P. (2018), Immunogenicity of plant-produced African horse sickness virus-like particles: implications for a novel vaccine. Plant Biotechnol J, 16: 442–450. doi:10.1111/pbi.12783.en_ZA
dc.identifier.issn1467-7644 (print)
dc.identifier.issn1467-7652 (online)
dc.identifier.other10.1111/pbi.12783
dc.identifier.urihttp://hdl.handle.net/2263/61791
dc.language.isoenen_ZA
dc.publisherWileyen_ZA
dc.rights© 2017 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.en_ZA
dc.subjectBiopharmingen_ZA
dc.subjectTransient expressionen_ZA
dc.subjectVaccinesen_ZA
dc.subjectAfrican horse sickness (AHS)en_ZA
dc.subjectAfrican horse sickness virus (AHSV)en_ZA
dc.subjectVirus-like particle (VLP)en_ZA
dc.subjectCowpea mosaic virus-based HyperTrans (CPMV-HT)en_ZA
dc.titleImmunogenicity of plant-produced African horse sickness virus-like particles : implications for a novel vaccineen_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 5 of 7
Loading...
Thumbnail Image
Name:
Dennis_ImmunogenicityFigS1_2018.pdf
Size:
177.19 KB
Format:
Adobe Portable Document Format
Description:
Figure S1
Loading...
Thumbnail Image
Name:
Dennis_ImmunogenicityFigS2_2018.pdf
Size:
193.09 KB
Format:
Adobe Portable Document Format
Description:
Figure S2
Loading...
Thumbnail Image
Name:
Dennis_ImmunogenicityFigS3_2018.pdf
Size:
189.13 KB
Format:
Adobe Portable Document Format
Description:
Figure S3
Loading...
Thumbnail Image
Name:
Dennis_ImmunogenicityFigS4_2018.pdf
Size:
298.86 KB
Format:
Adobe Portable Document Format
Description:
Figure S4
Loading...
Thumbnail Image
Name:
Dennis_ImmunogenicityFigS5_2018.pdf
Size:
181.61 KB
Format:
Adobe Portable Document Format
Description:
Figure S5

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: